Alimera Sciences

Retinal Disease
is Our Focus

Moving the back of the eye to the forefront
of research and development.

Learn more about our goals »

ILUVIEN: Investigational Treatment for DME

ILUVIEN® fluocinolone acetonide intravitreal insert 0.19mg

Investigational Treatment For DME

Providing the diabetic patient with a low-drug exposure, sustained-release treatment for Diabetic Macular Edema.

Learn more about how ILUVIEN works »

Diabetes is the leading cause of new cases of blindness in adults

DIABETES and
VISION LOSS

Diabetes is the leading cause of new cases of blindness in adults.

Learn how Alimera Sciences is creating reliable, effective treatments for diabetic retinopathy »

Latest News

View All Recent News »

Alimera Sciences Reports First Quarter 2012 Financial Results

May 11, 2012 -- Alimera Sciences, Inc., (Alimera), a biopharmaceutical company that specializes in the research,...

Read More »

United Kingdom Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema

May 07, 2012 -- Alimera Sciences, Inc., (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the Medicines and Healthcare products Regulatory...

Read More »

Alimera Sciences to Release First Quarter Fiscal Year 2012 Financial Results

April 26, 2012 -- Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter fiscal...

Read More »